J. Desantis

发表

2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors

M. Loza, J. Brea, T. Pihlajaniemi, 2018, Scientific Reports.

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications

L. Goracci, G. Cruciani, J. Desantis, 2020, Journal of medicinal chemistry.

CROMATIC: Cross-Relationship Map of Cavities from Coronaviruses

Lydia Siragusa, L. Goracci, G. Cruciani, 2022, J. Chem. Inf. Model..

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization

Lydia Siragusa, L. Goracci, G. Cruciani, 2022, Antiviral Research.

Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives.

L. Goracci, A. Loregian, Giulio Nannetti, 2017, Organic & biomolecular chemistry.

Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.

L. Goracci, G. Palù, A. Loregian, 2017, European journal of medicinal chemistry.

A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.

L. Goracci, G. Cruciani, G. Palù, 2015, Journal of medicinal chemistry.

PROTACs bearing piperazine-containing linkers: what effect on their protonation state?

L. Goracci, A. Mammoli, A. Macchiarulo, 2022, RSC advances.

Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.

E. Wanker, P. Carloni, G. Rossetti, 2018, ACS chemical neuroscience.

Proteolysis targeting chimeras in antiviral research.

L. Goracci, J. Desantis, 2022, Future medicinal chemistry.

Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design

Lydia Siragusa, S. Cross, C. Vacca, 2022, International journal of molecular sciences.

An overview on small molecules acting as broad-spectrum agents for yellow fever infection

J. Desantis, R. Cannalire, T. Felicetti, 2022, Expert opinion on drug discovery.

1,2,4-Triazolo[1,5-a]pyrimidines as a Novel Class of Inhibitors of the HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity

C. Pannecouque, E. Tramontano, S. Sabatini, 2020, Molecules.

Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.

C. Pannecouque, O. Tabarrini, L. Bagnoli, 2015, Journal of medicinal chemistry.

Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.

J. Handzlik, A. Bojarski, G. Satała, 2020, European journal of medicinal chemistry.

Characteristics of residues from wet air oxidation of anaerobic sludges

J. E. Smith, A. A. Friedman, T. Ptak, 1988 .

From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors

C. Pannecouque, E. Tramontano, S. Sabatini, 2018, Journal of enzyme inhibition and medicinal chemistry.

Studies on Cycloheptathiophene‐3‐carboxamide Derivatives as Allosteric HIV‐1 Ribonuclease H Inhibitors

C. Pannecouque, E. Tramontano, S. Sabatini, 2016, ChemMedChem.

Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy

Roy J. Vaz, G. Cruciani, Wun-Jae Kim, 2020, Molecular Cancer Therapeutics.

Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.

Serena Massari, O. Tabarrini, J. Desantis, 2016, Future medicinal chemistry.

Design and Synthesis of WM5 Analogues as HIV-1 TAR RNA Binders

C. Pannecouque, B. Gatto, G. Manfroni, 2019, The Open Medicinal Chemistry Journal.

4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.

B. Lüscher, Serena Massari, O. Tabarrini, 2018, European journal of medicinal chemistry.

Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Protein-Protein Interaction as a Target for Next-Generation Anti-influenza Therapeutics.

L. Goracci, Serena Massari, O. Tabarrini, 2016, Journal of medicinal chemistry.

Indomethacin-based PROTACs as pan-coronavirus antiviral agents

Lydia Siragusa, L. Goracci, G. Cruciani, 2021, European Journal of Medicinal Chemistry.

Potent and broad‐spectrum cycloheptathiophene‐3‐carboxamide compounds that target the PA‐PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance

G. Palù, A. Loregian, B. Mercorelli, 2019, Antiviral research.

Inhibition of Influenza Virus Polymerase by Interfering with Its Protein–Protein Interactions

Serena Massari, O. Tabarrini, V. Cecchetti, 2020, ACS infectious diseases.

VHL-Modified PROteolysis TArgeting Chimeras (PROTACs) as a Strategy to Evade Metabolic Degradation in In Vitro Applications.

L. Goracci, J. Desantis, Beatrice Castellani, 2023, Journal of Medicinal Chemistry.

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib

L. Goracci, J. Desantis, Stefano Bonciarelli, 2023, ACS omega.

A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.

G. Cruciani, G. Palù, A. Loregian, 2015, Journal of medicinal chemistry.